In a report released on August 18, David Risinger from SVB Securities maintained a Buy rating on HilleVax, Inc (HLVX – Research Report). The company’s shares closed yesterday at $10.89.
According to TipRanks, Risinger is a 2-star analyst with an average return of -0.6% and a 35.71% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Pfizer, Sanofi, and Eli Lilly & Co.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for HilleVax, Inc with a $32.67 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $20.95 and a one-year low of $7.90. Currently, HilleVax, Inc has an average volume of 141.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm’s initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Read More on HLVX:
- Snowflake (SNOW) Receives a Buy from Robert W. Baird
- Robert W. Baird Sticks to Their Hold Rating for Amcor (AMCR)
- Why Goodyear Tire (NASDAQ:GT) Stock’s Recent Momentum Can Fade
- Global hotel tech leader SiteMinder expands hotel commerce platform with acquisition of GuestJoy
- Analysts Are Bullish on Top Financial Stocks: Scentre Group (STGPF), Emeco Holdings Limited (EOHDF)
